VISION
PentixaPharm is committed to developing the innovative theranostic pair PentixaFor and PentixaTher. PentixaFor and PentixaTher are two-small peptide-based radiopharmaceuticals which specifically target the CXCR4-receptor expressed in most fast progressing diseases such as hematological and solid cancers as well as cardiovascular malignancies.
MANAGEMENT TEAM
With a solid history of building successful radiopharmaceutical start-ups, the PentixaPharm management team incorporates personal experience in all key functions of an early stage radiopharmaceutical development company: clinical development, manufacturing as well as organizational and financial set-up.
DR. HAKIM BOUTERFA
CLINIC
Managing Director,
PentixaPharm GmbH
Co-Founder, Managing Director,
1717 LSV GmbH
Co-Founder, former Managing Director, OctreoPharm Sciences GmbH
Former Vice President Europe, Molecular Insight Pharmaceuticals GmbH
Former Global Medical Director Sandostatin, Novartis Pharma AG, (revenues > $ 1 BN p.a.)
Done >50 % coordinated > 200 clinical studies in Phase I – IV
Studied Human Biology (PhD) and Medicine, Universities Marburg & Göttingen
ANNA STEEGER
FINANCE
Managing Director,
PentixaPharm GmbH
Co-Founder, Managing Director,
1717 LSV GmbH
Former Portfolio Manager,
Full Power of Attorney, Eckert Life Science Accelerator GmbH
Former Head of Finance & Administation, OctreoPharm Sciences GmbH
Founder Polyventures GmbH
Former Member of Board of Directors, EZ Bebig s.a.
Studied Business (Master), Universities Sydney & Zurich
DR. JENS KAUFMANN
MANUFACTURING
Managing Director,
PentixaPharm GmbH
Co-Founder, Managing Director,
1717 LSV GmbH
Former Director RP Development, Ipsen AG
Former Head RP Development, OctreoPharm Sciences GmbH
Former Head of Chemical Product and Process Development,
Eckert & Ziegler AG
Studied Chemistry (PhD),
Technical University of Berlin
Headquarter
Bismarckstraße 13
97080 Würzburg
Germany
Fon +49 931 991360-76
Robert-Rössle-Str. 10
13125 Berlin
Germany
Fon +49 30 9489-3220